Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors

NCT03842865 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT03842865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03842865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Expanded Access Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Advanced Solid Tumors
Lead sponsor
Gradalis, Inc.
Phase
Expanded access
Overall status
Temporarily not available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gynecological cancers, cervical cancer, ewing sarcoma, ewing's sarcoma metastatic, ewing's tumor metastatic, ovarian cancer, solid tumor, uterine cancer